New hope for advanced breast cancer patients who have run out of options
Disease control
Ongoing
This study is testing a new three-drug combination (gedatolisib, fulvestrant, and palbociclib) against standard treatments for people with advanced HR+/HER2- breast cancer. It is for patients whose cancer has continued to grow despite prior treatment with a common type of hormone…
Phase: PHASE3 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC